Today's News |
NervGen Pharma Announces Appointment of Dr. Matvey Lukashev as Vice President, Research and Preclinical Development
Monday, September 19, 2022Company Profile | Follow Company
Vancouver, BC, September 19, 2022--(T-Net)--NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing solutions for the treatment of nervous system damage, announced the appointment of Matvey Lukashev, PhD, as the Company's Vice President, Research and Preclinical Development.
Paul Brennan, President and Chief Executive Officer, NervGen Pharma Corp.
"We are delighted to welcome Dr. Lukashev to our team," stated Paul Brennan, President & CEO of NervGen. "Matvey will lead an important evolution at NervGen as we emphasize the development of our lead drug candidate, NVG-291, beyond our initial formulation and core indications, and build a pipeline of additional proprietary compounds that address nervous system repair. Matvey has over 20 years of industry experience in discovery and translational research, including 14 years at Biogen where he led target and drug discovery, as well as translational research programs in several therapeutic areas and was responsible for translational research supporting the clinical development of Tecfidera, a multiple sclerosis therapy that reached annual sales over $4 billion. Most recently, Matvey was at the ALS Therapy Development Institute in Massachusetts where he built and led the Augie's Quest Translational Research Center. This experience puts Matvey in an excellent position to lead our research and preclinical development efforts."
"I am excited to be joining NervGen at this stage of its growth and development," said Dr. Lukashev. "I see tremendous potential for the novel therapeutic modality provided by NVG-291 as we progress through the clinical studies and look forward to supporting the program going forward. Additionally, the learnings we gain during the development of NVG-291 will help us build a pipeline of new therapeutics complementing NVG-291. The field of nervous system repair is a therapeutic area of great unmet medical need where substantial advances can be made to benefit patients suffering from nervous system trauma or neurodegenerative diseases."
Dr. Lukashev has over 30 years of research experience in academia, industry, and non-profit biotech settings. Most recently, Dr. Lukashev served as Vice-President, Translational Sciences at the ALS Therapy Development Institute where he built and led a new translational research and drug discovery function encompassing patient genomics, stem cell biology, genome editing and phenotypic screening for biomarker, target and drug discovery in amyotrophic lateral sclerosis.
Prior to joining the ALS Therapy Development Institute, Dr. Lukashev held positions of increasing responsibility at Biogen, where he received the Biogen Idec Outstanding Achievement Award for his leadership of translational studies supporting clinical development of Tecfidera®. Dr. Lukashev obtained his doctorate in Cell Biology from the USSR Academy of Medical Sciences and received postdoctoral training at John Hopkins University and University of California, San Francisco.
About NervGen
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen's lead drug candidate, NVG-291, is currently in a Phase 1 clinical trial. The company's initial target indications are spinal cord injury, Alzheimer's disease, and multiple sclerosis. For more information, go to www.nervgen.com.
About NVG-291
NervGen holds the exclusive worldwide rights to NVG-291 and is developing a unique new class of drugs around the technology. NVG-291 is a therapeutic peptide that mimics the intracellular domain of the receptor protein tyrosine phosphatase sigma (PTPs), a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs). Both PTPs and CSPGs have been shown to inhibit neural repair mechanisms following nervous system damage.
NVG-291-R, the rodent form of NVG-291, has been shown to promote functional recovery and enable nervous system repair in a range of animal models, including models of spinal cord injury, peripheral nerve injury, multiple sclerosis, and stroke, through enhanced plasticity, axonal regeneration, and remyelination.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation. Such forward-looking statements and information herein include, but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: our development programs, including the development of NVG-291; our research for the treatment of spinal cord injury, multiple sclerosis, Alzheimer's disease and other neurodegenerative applications; and the use of proceeds of the Offering. [ MORE ] |
Other Recent Company News |
||||||||||||||||||||
|